NEVVI Medicare utilization intelligence

← back

KAIROUZ, SEBASTIENM.D. NPI 1396701009 Clinician

Medical Oncology · DECATUR, IL

Specialty Medical Oncology — from billed Medicare claims
In practice about 31 years since medical school (class of 1995, self-reported to CMS)
Location DECATUR, IL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 80 codes billed · 144,729 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS SC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2014-02

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J0897 Injection, denosumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J0640 Injection, leucovorin calcium, per 50 mg
J2469 Injection, palonosetron hcl, 25 mcg
80053 Blood test, comprehensive group of blood chemicals
36415 Insertion of needle into vein for collection of blood sample
96375 Injection of additional new drug or substance into vein
J9190 Injection, fluorouracil, 500 mg
83735 Magnesium level
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
85007 Microscopic examination for white blood cells with manual cell count
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
82784 Gammaglobulin (immune system protein) measurement
88185 Flow cytometry technique for dna or cell analysis, each additional marker
96413 Administration of chemotherapy into vein, 1 hour or less
83615 Lactate dehydrogenase (enzyme) level
96372 Injection of drug or substance under skin or into muscle
82378 Carcinoembryonic antigen (cea) protein level
83521 Measurement of immunoglobulin light chains
96361 Infusion into a vein for hydration, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96374 Injection of drug or substance into vein
83540 Iron level
83550 Iron binding capacity
82728 Ferritin (blood protein) level
96415 Administration of chemotherapy into vein, each additional hour
J7030 Infusion, normal saline solution , 1000 cc
96417 Administration of additional new drug or substance into vein, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J3475 Injection, magnesium sulfate, per 500 mg
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
J3489 Injection, zoledronic acid, 1 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96411 Administration of additional new drug or substance into vein using push technique
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
71260 Ct scan of chest with contrast
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96523 Irrigation of implanted venous access drug delivery device
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
74177 Ct scan of abdomen and pelvis with contrast
84443 Blood test, thyroid stimulating hormone (tsh)
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
84153 Psa (prostate specific antigen) measurement, total
36591 Collection of blood sample from implanted device
83010 Haptoglobin (serum protein) level
96360 Infusion into a vein for hydration, 31-60 minutes
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
82668 Erythropoietin (protein) level
82232 Beta-2 microglobulin (protein) level
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
81001 Manual urinalysis test with examination using microscope, automated
80061 Blood test, lipids (cholesterol and triglycerides)
82306 Vitamin d-3 level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
84439 Thyroxine (thyroid chemical), free
84550 Uric acid level, blood
77080 Dxa bone density measurement of hip, pelvis, spine
88184 Flow cytometry technique for dna or cell analysis, first marker
38222 Biopsy and aspiration of bone marrow sample for diagnosis
71250 Ct scan of chest without contrast
84100 Phosphate level
85045 Red blood count, automated test

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.